European Notebook: Sanofi Exiting Toulouse; Job Cuts At Pierre Fabre; Generics Suspended In Four States
This article was originally published in The Pink Sheet
The newly formed European Commission sets out plans to improve industrial growth and international trade while leading French pharma companies Sanofi and Pierre Fabre announce plans to trim their R&D workforces. Asian companies in contrast are seeking growth opportunities in Europe, including India’s Cipla and Thailand’s CP Group.
You may also be interested in...
British life sciences minister George Freeman has launched ambitious plans to speed access to drugs by cutting drug development times by a third – but his plans face many hurdles.
Sanofi says it will cut up to 900 jobs in France over the next three years to make its R&D operations there more efficient – that’s less than half the number foreshadowed in July by French trade unions and after the drug maker came under public pressure from the country’s left-wing government.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.